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Data presented in this article are supplementary material to our
article entitled “Identiﬁcation and diagnosis of patients with
familial chylomicronaemia syndrome (FCS): expert panel recom-
mendations and proposal of an “FCS Score” (Moulin et al., 2018, in
press). The data describe the genotypes of patients with familial
chylomicronaemia syndrome (FCS) and multifactorial chylomicro-
naemia syndrome (MCS), from the validation and replication
cohorts.
& 2018 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Medicine
ore speciﬁc subject area Hypertriglyceridaemia
ype of data Text ﬁle, Table
ow data was acquired Retrospectively. Clinical history and genotyping of patients
ata format Summary of raw data
xperimental factors Retrospective analysis of patient records
xperimental features The cut-off for the familial chylomicronaemia syndrome score was
determined from a validation cohort and tested on replication cohorts
ata source location Lyon, France; Montréal, Canada; Rome, Italy; Palermo, Italy
ata accessibility Data are within this articleValue of the data
 Summary data from relatively large cohorts of familial chylomicronaemia syndrome (FCS) and
multifactorial chylomicronaemia syndrome (MCS) patients.
 The data illustrate how a cut-off level of Z10 for the FCS clinical diagnostic score [1] may help to
differentiate between FCS and MCS patients.
 The data provide a benchmark for future studies.1. Data
The familial chylomicronaemia syndrome (FCS) cohort included 25 patients with FCS from the
Montreal lipid clinic and four patients from the Lyon lipid clinic (Table 1). The multifactorial chylo-
micronaemia syndrome (MCS) cohort included 29 patients consecutively studied over the previous
2 years in the Lyon lipid clinic (Table 1). The FCS cohort was used to establish sensitivity and the MCS
cohort was used to establish speciﬁcity, leading to a receiver operating characteristic (ROC) curve area
of 0.91 [1]. Replication of the diagnosis capacity of the FCS score was retrospectively tested in two
additional lipid clinics. The Rome replication cohort included 16 patients with FCS and 15 patients
with MCS (Table 1). The Palermo replication cohort included eight patients with FCS and eight
patients with MCS (Table 1).
Table 1
Hypertriglyceridaemic patients: genotypes found in the different cohorts.
FCS MCS
Ho LPL Comp
He LPL
Ho not LPL Comp He
not LPL
WT low LPL
activity
He Pol WT NA
Montreal 15 7 1 0 2
Lyon 3 1 11 8 5 5
Rome 8 1 5 2 11 4
Palermo 6 0 2 1 2 3 2
FCS, familial chylomicronaemia syndrome; MCS, multifactorial chylomicronaemia syndrome; Ho, homozygous; LPL, lipoprotein
lipase; Comp, compound; He, heterozygous; WT, wild type; Pol, multiple functional SNPs; NA, not available.
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The items of the FCS score were selected on a pragmatic basis following discussion within a panel of
experts. The relative weight of each item was set up also on a pragmatic basis. The cut-off was
determined from a validation cohort and tested on replication cohorts. FCS patients were deﬁned as any
patient carrier of a homozygous or a compound heterozygous loss of function mutation in lipoprotein
lipase (LPL), apolipoprotein C2 (APOC2), apolipoprotein A5 (APOA5), glycosylphosphatidylinositol-
anchored high-density lipoprotein-binding protein 1 (GPIHBP1) and lipase maturation factor 1 (LMF1)
genes or a low post-heparin LPL activity. MCS patients were deﬁned as patients with documented
history of plasma triglyceride (TG) 410mmol/L and carriers of either a heterozygous loss of function
mutation and/or variants associated with increased TG level in LPL, APOC2, APOA5, GPIHBP1 and
LMF1 genes.
In the patients with MCS, due to the retrospective design, the plasma TG concentration was
considered to be consistently 410mmol/L in order to challenge the speciﬁcity of the FCS score, if not
enough information was available in the medical ﬁle regarding the reproducibility of the plasma TG
concentration 410mmol/L. Further study is needed to prospectively validate the score in cohorts
with comprehensive phenotype available.
All the patients gave written, informed consent for genotyping. All the French patients received
written information regarding the study according to the French bioethics Law Jardé 2017.Acknowledgements
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